Document registry — page 22
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Sub-visible particulate matter in reconstituted peptide solutions
High24 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
17 Jul 2025 -
Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an efficacy and tolerability profile comparable with an injectable presentation?
Moderate16 Jul 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Survodutide compared with its…
Moderate15 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Jul 2025 -
Peptides, SARMs, injectable oils and raw materials.
11 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity randomising 610 participants over 48 weeks. Primary result: Mean change −14.0 % at 6…
Moderate09 Jul 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Jul 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jul 2025 -
Consultation on the second version of the tirzepatide monograph, which incorporates the obesity evidence from SURMOUNT-1, reported in the New England Journal of Medicine…
02 Jul 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Teduglutide compared with the comparator used in its…
Moderate28 Jun 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with…
High27 Jun 2025 -
GLP-1 receptor agonist (cAMP-biased, acylated). Selective GLP-1 receptor agonism with a reported bias towards Gαs-coupled cyclic-AMP signalling. Whether signalling bias translates into a clinically…
Low27 Jun 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
26 Jun 2025 -
Phase 1 ascending dose, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low25 Jun 2025 -
Consultation on the draft of CEI-MS-09, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
24 Jun 2025 -
Record of documents ratified in the 2025 Q2 assessment cycle.
22 Jun 2025 -
Consultation on the draft monograph for Selank, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
22 Jun 2025 -
What is the evidence for thymic peptides in chronic viral hepatitis, sepsis and non-specific immune support?
Low17 Jun 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its…
Moderate16 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes randomising 1,206 participants…
Moderate16 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low15 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Jun 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jun 2025 -
Consultation on the draft safety review of the rodent thyroid C-cell signal observed with glucagon-like peptide-1 receptor agonists and its relevance to humans. The…
13 Jun 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide)…
Moderate12 Jun 2025 -
Endogenous decapeptide, KISS1 receptor agonist. Kisspeptin acts on KISS1 receptors on hypothalamic gonadotropin-releasing hormone neurons to stimulate GnRH secretion, and thereby luteinising…
Low11 Jun 2025 -
Consultation on the comparison table that presents supplier dossiers side by side. The draft table shows only fields verified from a document the Institute holds, and…
10 Jun 2025 -
Randomised crossover, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low08 Jun 2025 -
Consultation on the draft of this methodological review, which registers the question: To what extent does a change in body weight predict a change in the clinical…
03 Jun 2025 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in obesity randomising 751 participants over 72 weeks. Primary result: Mean change −20.2 % with…
High28 May 2025 -
What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?
Very low26 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in mash randomising 1,197 participants over 72 weeks for part 1. Primary result: Resolution in…
Moderate26 May 2025 -
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body…
High23 May 2025 -
Determination of water content in lyophilised peptides by coulometric Karl Fischer titration
High23 May 2025 -
Single-arm open-label, phase 3 study of Orforglipron in obesity and type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low23 May 2025 -
Consultation on the draft monograph for TB-500, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
22 May 2025 -
What proportion of certificates of analysis supplied with research peptides contain the fields required to interpret the reported purity figure?
Moderate20 May 2025 -
GIP receptor antagonist and GLP-1 receptor agonist conjugate (antibody–peptide). GLP-1 receptor agonism supplies appetite suppression; GIP receptor antagonism is proposed to act on adipose tissue and central pathways in…
Low19 May 2025
page 22 of 41